RT Journal Article
SR Electronic
T1 Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e005611
DO 10.1136/jitc-2022-005611
VO 10
IS 9
A1 Vos, Winnie G
A1 Lutgens, Esther
A1 Seijkens, Tom T P
YR 2022
UL http://jitc.bmj.com/content/10/9/e005611.abstract
AB In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI efficacy are therefore needed. The widespread clinical use of ICIs has increased our knowledge on the effects of the concomitant use of commonly prescribed drugs on the outcome of ICI treatment. A particular interesting class of drugs in this context are statins. These HMG-CoA reductase inhibitors, which are used to treat hypercholesterolemia and reduce the risk for atherosclerotic cardiovascular disease, are frequently used by patients with (advanced) cancer. This paper addresses the hypothesis that statins improve the efficacy of ICI therapy.